Online inquiry

IVTScrip™ mRNA-Anti-NGF, PF-04383119(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13161MR)

This product GTTS-WQ13161MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets NGF gene. The antibody can be applied in Osteoarthritis (OA) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001194950.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 403402
UniProt ID F1PDQ3
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-NGF, PF-04383119(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ13161MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ2197MR IVTScrip™ mRNA-Anti-IL15, ALT-803(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ALT-803
GTTS-WQ12600MR IVTScrip™ mRNA-Anti-F11, NVS250519(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA NVS250519
GTTS-WQ5845MR IVTScrip™ mRNA-Anti-CD40, CHIR-12,12(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CHIR-12,12
GTTS-WQ2902MR IVTScrip™ mRNA-Anti-IL17RA, AMG827(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG827
GTTS-WQ2551MR IVTScrip™ mRNA-Anti-GCGR, AMG 477(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 477
GTTS-WQ13548MR IVTScrip™ mRNA-Anti-GPI-APs, PRX-302(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PRX-302
GTTS-WQ769MR IVTScrip™ mRNA-Anti-LOXL2, AB0024(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA AB0024
GTTS-WQ14654MR IVTScrip™ mRNA-Anti-DPEP3, SC-003 mAb(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SC-003 mAb
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW